专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110300179A1 Novel Compositions and Uses Thereof 审中-公开
标题翻译：小说作品及其用途
公开(公告)号：US20110300179A1
公开(公告)日：2011-12-08
申请号：US12514219
申请日：2007-11-12
申请人： Anna-Lena Spetz-Holmgren , Ulrika Johansson , Jan Andersson , Lilian Walther-Jallow
发明人： Anna-Lena Spetz-Holmgren , Ulrika Johansson , Jan Andersson , Lilian Walther-Jallow
IPC分类号： A61K39/39 , A61K39/02 , A61K39/12 , A61K39/002 , A61K39/21 , A61K39/04 , A61K39/112 , A61K39/095 , A61K39/118 , A61K39/102 , A61K39/015 , A61P37/04 , A61P31/18 , A61P31/20 , A61P31/22 , A61P31/14 , A61P31/00 , A61P31/10 , A61P31/04 , A61P31/06 , A61P33/02 , A61P33/06 , C12N5/0783
CPC分类号： A61K39/39 , A61K2039/515 , C12N5/0636 , Y02A50/412 , Y02A50/466
摘要： The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. In addition, the invention provides a composition having microbicide activity, or capable thereof upon exposure to antigen-presenting cells, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. Also provided by the present invention are methods for making and using the vaccines and compositions described herein.
摘要翻译：本发明提供了用于治疗或预防性治疗病理状况的细胞疫苗，所述疫苗包含或修饰为包含抗原成分的CD4 + T细胞群体，和/或编码抗原性的核酸分子其组分，其中所述T细胞是（a）活化的或能够被活化的，和（b）凋亡的，或能够或被制成凋亡的。本发明还提供了一种用于接种方法的佐剂组合物，所述组合物包含T细胞群体或由其组成，其中所述T细胞是（a）活化的或能够被活化的，和（b）凋亡的，或能够或正在被凋亡。此外，本发明提供了具有杀微生物剂活性的组合物，或者其在暴露于抗原呈递细胞时能够组合，所述组合物包含T细胞群体或由其组成，其中T细胞是（a）被激活或能够被活化，和（b）凋亡，或能够或被凋亡。本发明还提供了制备和使用本文所述疫苗和组合物的方法。

2. 发明申请

US20090263421A1 CELLULAR VACCINE 审中-公开
标题翻译：细胞疫苗
公开(公告)号：US20090263421A1
公开(公告)日：2009-10-22
申请号：US11914087
申请日：2006-05-10
申请人： Anna-Lena Spetz-Holmgren , Ulrika Johansson , Jan Anderson , Lilian Walther-jallow
发明人： Anna-Lena Spetz-Holmgren , Ulrika Johansson , Jan Anderson , Lilian Walther-jallow
IPC分类号： A61K39/145 , A61K45/00 , A61K39/12 , A61K39/29 , A61K39/205 , A61K39/275 , A61K39/02 , A61K39/118 , A61K39/095 , A61K39/102 , A61P37/04
CPC分类号： A61K39/00 , A61K2039/515 , A61K2039/5156 , C12N5/0636 , C12N5/0639 , Y02A50/412 , Y02A50/466
摘要： The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. In addition, the invention provides a composition having microbicide activity, or capable thereof upon exposure to antigen-presenting cells, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. Also provided by the present invention are methods for making and using the vaccines and compositions described herein.
摘要翻译：本发明提供了用于治疗或预防性治疗病理状况的细胞疫苗，所述疫苗包含或修饰为包含抗原成分的CD4 + T细胞群体，和/或编码抗原性的核酸分子其组分，其中所述T细胞是（a）活化的或能够被活化的，和（b）凋亡的，或能够或被制成凋亡的。本发明还提供了一种用于接种方法的佐剂组合物，所述组合物包含T细胞群体或由其组成，其中所述T细胞是（a）活化的或能够被活化的，和（b）凋亡的，或能够或正在被凋亡。此外，本发明提供了具有杀微生物剂活性的组合物，或者其在暴露于抗原呈递细胞时能够组合，所述组合物包含T细胞群体或由其组成，其中T细胞是（a）被激活或能够被激活，和（b）凋亡，或能够或被凋亡。本发明还提供了制备和使用本文所述疫苗和组合物的方法。

3. 发明授权

US06506596B2 Method of DNA transfer 失效
公开(公告)号：US06506596B2
公开(公告)日：2003-01-14
申请号：US09842073
申请日：2001-04-26
申请人： Anna-Lena Spetz-Holmgren , Lars Holmgren , Jan Andersson , Judah Folkman
发明人： Anna-Lena Spetz-Holmgren , Lars Holmgren , Jan Andersson , Judah Folkman
IPC分类号： C12N500
CPC分类号： A61K39/21 , A61K39/12 , A61K48/00 , A61K2039/5154 , A61K2039/5156 , A61K2039/53 , A61K2039/57 , C12N15/87 , C12N2710/16234 , C12N2740/16034
摘要： The present invention relates to a method of of transferring genomic DNA from apoptotic bodies to engulfing cells, wherein DNA is transferred from a donor cell to a recipient cell. More specifically the method includes providing somatic donor cells comprising desired DNA; generating apoptotic bodies of said donor cells; incubation of the apoptotic bodies with engulfing recipient cells under biological conditions allowing uptake of DNA from the apoptotic bodies by said recipient cells; and optionally selecting recipient cells which have integrated DNA from the apoptotic bodies. The present method is useful in various pharmaceutical applications, such as in vaccine preparations and gene identification procedures. Further, the present invention also relates to a method of preventing and/or treating a clinical condition in a patient, which comprises isolating cells comprising genomic DNA; generating apoptotic bodies of said isolated cells; incubation of said apoptotic bodies with engulfing recipient cells under biological conditions allowing uptake of DNA from the apoptotic bodies, optionally, selecting cells containing DNA originating from the isolated cells; and administering cells in a pharmaceutically acceptable carrier to the patient, thus enabling a protective and/or therapeutic reaction against the clinical condition.

4. 发明申请

US20180142246A1 Single-Stranded Oligonucleotides for Use in the Medical Treatment of Skin Disorders 审中-公开
公开(公告)号：US20180142246A1
公开(公告)日：2018-05-24
申请号：US15736020
申请日：2016-06-14
申请人： Anna-Lena Spetz Holmgren , Peter Jarver , Annette Skold
发明人： Anna-Lena Spetz Holmgren , Peter Jarver , Annette Skold
IPC分类号： C12N15/117 , A61P17/00
CPC分类号： C12N15/117 , A61K31/7125 , A61K45/06 , A61P17/00 , C12N2310/17 , C12N2310/315 , C12N2310/321 , C12N2310/346 , A61K2300/00 , C12N2310/3521
摘要： The invention relates to non-CpG single-stranded oligonucleotides (ssONs) for use in the treatment or prophylaxis of disorders of the skin and/or subcutaneous tissue, including pruritus, in a suitable formulation or in combination with other immunomodulatory treatments. The said ssONs have a length of at least 25 nucleotides and are stabilized by phosphorothioate internucleotide linkages and/or 2′-O-Methyl modifications.

5. 发明申请

US20100040589A1 Novel Compositions and Uses Thereof 审中-公开
标题翻译：小说作品及其用途
公开(公告)号：US20100040589A1
公开(公告)日：2010-02-18
申请号：US12514233
申请日：2007-11-12
申请人： Anna-Lena Spetz-Holmgren , Ulrika Johansson , Lilian Walther-Jallow , Jan Andersson
发明人： Anna-Lena Spetz-Holmgren , Ulrika Johansson , Lilian Walther-Jallow , Jan Andersson
IPC分类号： A61K45/00 , A61P37/04 , A61P31/04 , A61P31/12 , A61P31/18
CPC分类号： A61K39/21 , A61K39/12 , A61K39/39 , A61K2035/124 , A61K2039/5154 , A61K2039/5156 , A61K2039/555 , A61K2039/55588 , A61K2039/57 , C12N5/0636 , C12N2501/48 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2740/13034 , C12N2740/15034 , C12N2740/16034 , Y02A50/412 , Y02A50/466
摘要： The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. In addition, the invention provides a composition having microbicide activity, or capable thereof upon exposure to antigen-presenting cells, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. Also provided by the present invention are methods for making and using the vaccines and compositions described herein.
摘要翻译：本发明提供了用于治疗或预防性治疗病理状况的细胞疫苗，所述疫苗包含或修饰为包含抗原成分的CD4 + T细胞群体，和/或编码抗原性的核酸分子其组分，其中所述T细胞是（a）活化的或能够被活化的，和（b）凋亡的，或能够或被制成凋亡的。本发明还提供了一种用于接种方法的佐剂组合物，所述组合物包含T细胞群体或由其组成，其中所述T细胞是（a）活化的或能够被活化的，和（b）凋亡的，或能够或正在被凋亡。此外，本发明提供了具有杀微生物剂活性的组合物，或者其在暴露于抗原呈递细胞时能够组合，所述组合物包含T细胞群体或由其组成，其中T细胞是（a）被激活或能够被活化，和（b）凋亡，或能够或被凋亡。本发明还提供了制备和使用本文所述疫苗和组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式